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ABSTRACT
The duration of action of adenosine A2A receptor (A2A) agonists is
critical for their clinical efficacy, and we sought to better understand
how this can be optimized. The in vitro temporal response profiles
of a panel of A2A agonists were studied using cAMP assays in
recombinantly (CHO) and endogenously (SH-SY5Y) expressing
cells. Some agonists (e.g., 3cd; UK-432,097) but not others (e.g.,
3ac; CGS-21680) demonstrated sustained wash-resistant ago-
nism, where residual receptor activation continued after washout.
The ability of an antagonist to reverse pre-established agonist
responses was used as a surrogate read-out for agonist dissoci-
ation kinetics, and together with radioligand binding studies
suggested a role for slow off-rate in driving sustained effects. One
compound, 3ch, showedparticularlymarked sustained effects,with
a reversal t1/2. 6 hours and close tomaximal effects that remained
for at least 5 hours after washing. Based on the structure-activity
relationship of these compounds, we suggest that lipophilic N6 and
bulky C2 substituents can promote stable and long-lived binding
events leading to sustained agonist responses, although a high
compound logD is not necessary. This provides new insight into the
binding interactions of these ligands and we anticipate that this
information could facilitate the rational design of novel long-acting
A2A agonists with improved clinical efficacy.
Introduction
The adenosine receptors are G protein-coupled receptors
(GPCRs) that comprise four subtypes (A1, A2A, A2B, and A3)
and mediate the physiologic effects of their endogenous
agonist adenosine. The adenosine A2A receptor (A2A) is
coupled to the stimulatory G protein (Gas) and signals through
cAMP pathways (Zezula and Freissmuth, 2008). A2A has a
wide tissue distribution and plays many important roles such
as in vasodilation, inflammation, and regulating neurotrans-
mitter release (de Lera Ruiz et al., 2014). As a primary target
of caffeine, A2A is involved in adenosine’s control of wakeful-
ness (Chen et al., 2013).
A2A is an important drug discovery target. The A2A-
selective agonist regadenoson is used clinically as a phar-
macological stress agent for myocardial imaging (Chen et al.,
2013). A2A agonists have anti-inflammatory properties and
are thus targeted for the potential treatment of chronic
obstructive pulmonary disease, asthma, allergic rhinitis,
sickle cell disease, and wound healing, among others, with
a number of compounds (e.g., UK-432,097; compound 3cd in
Table 1) reaching clinical trials (Mantell et al., 2010; Field
et al., 2013). The A2A agonist BVT.115959 has also been in
trials for diabetic neuropathic pain (Gao and Jacobson,
2011). Owing to its role in brown adipose activation, A2A
agonism was also recently postulated as an obesity therapy
(Gnad et al., 2014). Numerous potent and selective A2A
agonists have been developed, and these typically maintain
an adenosine structural scaffold with various substitutions
on the C2 and N6 positions of the molecule (de Lera Ruiz
et al., 2014) (Table 1). Crystal structures of agonist-bound
A2A have been solved, providing insight into the molecular
mechanisms of receptor function (Lebon et al., 2011, 2015; Xu
et al., 2011).
This work was funded by AstraZeneca as part of the Innovative Medicines
Initiative Joint Undertaking under K4DD, grant agreement no. 115366,
resources of which are composed of financial contribution from the European
Union’s Seventh Framework Programme [FP7/2007-2013] and EFPIA compa-
nies’ in kind contribution.
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s This article has supplemental material available at molpharm.
aspetjournals.org.
ABBREVIATIONS: A2A, adenosine A2A receptor; A2B, adenosine A2B receptor; FCS, fetal calf serum; GPCR, G protein-coupled receptor; HTRF,
homogenous time-resolved fluorescence; IAM, immobilized artificial membrane; KIAM, immobilized artificial membrane partitioning coefficient; KRI,
kinetic rate index; SAR, structure-activity relationship.
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TABLE 1
Summary of the compounds investigated in this study
All the ligands have an adenosine scaffold, with substitution on the ribose 4 position (R1), N6 (R2), and/or C2 (R3). Otsuka-3 is an exception, because it does not share this
structural scaffold. The individual structures of each compound are shown in Supplemental Fig. 1. References for compound disclosure; 1, (Marumoto et al., 1974); 2, (Bridges
et al., 1987); 3, (Åstrand et al., 2015); 4, (Sato et al., 2010). AZ proprietary compounds are marked # and their synthesis is described in Supplemental Figs. 1–6.
Compound number Synonym Ref. R1 R2 R3
1aa CV1808 1 H H
2bb R-PIA 2 CH2OH CH(R-Me)CH2Ph H
2cb 2 CH2OH CH2CHPh2 H
3ab NECA CONHEt H H
3ac CGS-21680 CONHEt H
3ad # CONHEt H
3cd UK-432,097 CONHEt CH2CHPh2
3ce # CONHEt CH2CHPh2
3cf # CONHEt CH2CHPh2
3ag # CONHEt H
(continued )
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Duration of action is a key property for targeting a desirable
clinical response profile for A2A agonists. To achieve a better
safety profile, short-lived activity has been optimized for
ligands developed as intravenous myocardial imaging agents
(Cerqueira, 2004). On the other hand, A2A agonists developed
for the treatment of chronic inflammatory diseases, such as
UK-432,097, have been targeted for local drug delivery to
minimize side effects (Mantell et al., 2010). A long duration of
target activity alongside appropriate physicochemical proper-
ties to aid tissue retention has been suggested to help achieve
efficacy through topical application (Mantell et al., 2010).
Therefore, for A2A drug discovery programs it is critical to
increase our understanding of the temporal response profiles
of drug candidates and the mechanisms through which long/
short duration of action can occur. Optimizing ligand binding
kinetics has been advocated as a valuable strategy for
achieving appropriate duration of action and target coverage
(Copeland et al., 2006; Guo et al., 2014; Hothersall et al., 2016).
Specifically, slow A2A agonist dissociation kinetics have been
cited as a potential mechanism to achieve a desirable clinical
response for topically applied drugs (Mantell et al., 2010). This
approachmay be especially relevant for A2Awhere the receptor
has been shown to signal without agonists inducing desensiti-
zation and internalization in recombinant systems as well as in
physiologic settings (Abbracchio et al., 1992; Adami et al., 1995;
Charalambous et al., 2008; Zezula and Freissmuth, 2008;
Baines et al., 2011), so long-lived agonist responses are possible.
In this study, we have assessed the temporal response
profiles of a range of A2A agonists in a recombinant (CHO cell)
and endogenous (SH-SY5Y cell) expression system. In wash-
out experiments, sustained receptor activation was observed
for some, but not all, agonists tested. Our evidence points
toward a predominant role for slow agonist off-rate in driving
wash-resistant responses. Coupled with structure-activity
relationships (SAR) for sustained effects, we can begin to
define the ligand-specific binding interactions that promote
TABLE 1—Continued
Compound number Synonym Ref. R1 R2 R3
3cg 3 CONHEt CH2CHPh2
3dg # CONHEt CH2CH(CH3)2
3eg # CONHEt CH(CH2CH3)2
3ah # CONHEt H
3ch 3 CONHEt CH2CHPh2
3dh # CONHEt CH2CH(CH3)2
3eh # CONHEt CH(CH2CH3)2
4 Otsuka-3 4 *
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stable and long-lived binding interactions and hence persis-
tent receptor activation.
Materials and Methods
Materials. Cell culture materials were from Life Technologies
(Paisley, UK) and Sigma Aldrich (Dorset, UK). GloSensor 22F plasmid
and luciferin were from Promega (Southampton, UK). Homogenous
time-resolved fluorescence (HTRF) dynamic cAMP kits were from
Cisbio (Codolet, France). Assay plates were from Greiner Bio One
(Stonehouse, UK). Adenosine and bovine spleen adenosine deaminase
(type X) were from Sigma Aldrich. Immobilized artificial membrane
chromatography columnswere fromRegis Technologies (Morton Grove,
IL). [3H]ZM-241385 (specific activity 28.4 Ci/mmol) was from American
Radiolabeled Chemicals Inc. (St. Louis, MO). Rolipram, CGS-21680
(2ac), NECA (3ab), and LUF5834 were from Tocris (Bristol, UK). All
other compounds were synthesized at WuXi PharmaTech (Shanghai,
China) or BioDuro (Beijing, China). The syntheses of new chemical
entities are described in Supplemental Figs. 1–6.
Cell Culture. CHO-K1 cells were cultured in Ham’s F-12 medium
supplemented with 10% fetal calf serum (FCS) in an atmosphere of 5%
CO2 at 37°C. Parental CHO cells were grown inmedium supplemented
with 100 U/ml penicillin and 100 mg/ml streptomycin. CHO cells stably
expressing human A2A (CHO-A2A) were grown in medium supple-
mented with 800mg/ml G-418. CHO cells stably expressing humanA2B
(CHO-A2B) were grown in medium supplemented with 200 mg/ml
hygromycin B. CHO cells stably expressing both human A2A and
GloSensor 22F were grown in medium supplemented with 800 mg/ml
G-418 and 200 mg/ml hygromycin B. HEK293 cells stably expressing
human A2A (HEK-A2A) were grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% FCS, 50 mg/ml streptomycin, 50 U/ml
penicillin, and 500 mg/ml G-418 in an atmosphere of 7% CO2 at 37°C.
SH-SY5Y cells were grown in a 1:1 mixture of Ham’s F-12 and
Dulbecco’s modified Eagle’s medium supplemented with 15% FCS, 1%
nonessential amino acids, 1 mM L-alanyl-L-glutamine, 100 U/ml peni-
cillin, and 100 mg/ml streptomycin in an atmosphere of 5% CO2 at 37°C.
Real-time cAMP Assay. GloSensor 22F (Promega) was used to
monitor real-time cAMP responses. CHO cells stably expressing both
A2A and GloSensor 22F plasmid (clonal isolates) were seeded into
white-bottomed tissue-culture treated 384-well plates at 15,000 cells
per well and grown for approximately 24 hours. Culture medium was
then replaced with assay buffer (Hank’s buffered saline solution 1
20 mM HEPES 1 10% FCS 1 0.8 U/ml adenosine deaminase, pH
7.4) supplemented with 612 mg/ml endotoxin-free beetle luciferin, and
cells were incubated at room temperature for 2 hours. Ten times
concentrated test compound was then manually added and lumines-
cence responses measured every 3.25 minutes over the indicated time
period at room temperature using an Envision plate reader (Perkin
Elmer, Waltham MA). In reversal experiments, a second addition of
antagonist was made in the same way.
Endpoint cAMP Assay. The endpoint cellular cAMP assay used
the homogenous time-resolved fluorescence (HTRF) Dynamic compet-
itive immunoassay kit (Cisbio), and methods were adapted from the
manufacturer’s instructions. Common to all endpoint experiments,
after cell treatment with compound(s), a 10 ml sample was added per
well to a black-bottomed 384-well plate. Dye-labeled cAMP followed by
anti-cAMP antibody (5 ml/well each, diluted in lysis buffer) were then
added and the plate was incubated at room temperature for 1–16
hours. To construct a standard curve, samples of known cAMP
concentration were also incubated in the same way. Fluorescence
was then read at 665 and 620 nm using an Envision plate-reader, and
a 665/620 ratio derived. Cellular cAMP concentration was calculated
by comparing these values (normalized to background fluorescence) to
the standard curve for each plate.
In washout experiments, suspensions of cells were treated with
compound and the cells were then physically isolated from the original
treatment vessel to remove nonspecific effects of compound interactions
with plastic. In 15 ml tubes, 2,400,000 cells per tube were resuspended
in 100 ml of assay buffer (Hank’s buffered saline solution 1 20 mM
HEPES 1 0.01% bovine serum albumin 1 0.8 U/ml adenosine de-
aminase, pH7.4) containing test compound and incubated for 2 hours at
37°C. This volume was used to minimize the contact area of compound
with plastic surfaces. After treatment, the buffer was then completely
removed by centrifugation (two cycles of spinning at 300 g for 5 minutes
to pellet cells and remove liquid) and cells were resuspended in 50 ml of
fresh buffer and subsequently transferred to a fresh tube containing
12 ml of drug-free buffer. This was repeated to give three cycles of
washing in three fresh tubes to remove the cells from any plastic
surfaces that had been exposed to a significant concentration of test
compound. Cells were incubated in the final tube for 1 hour at 37°C to
allow putative dissociation of compounds from the receptor. Cells were
then pelleted and resuspended in 2 ml buffer, transferred to 1.5 ml
tubes, and then exposed to 40 mM rolipram (1:1 dilution of cells) for
45 minutes at 37°C to capture cAMP accumulation. Aliquots (10 ml)
of each cell suspension were then added to HTRF assay plates, as
described above.
For antagonist reversal experiments performed with the endpoint
cAMP assay, cells adhered to collagen-coated 96-well plates were
used. Cells were seeded at 20,000 cells/well (for CHO cells) or 40,000
cells/well (for SH-SY5Y cells) in culture media and grown for
approximately 24 hours. Cells were then treated with test compound
in 50 ml assay buffer (Hank’s buffered saline solution 1 20 mM
HEPES 1 0.8 U/ml adenosine deaminase, pH 7.4) for the indicated
time. Antagonist or vehicle control was then directly added to the
wells for the indicated period to follow a time course of antagonist
reversal. Signaling was terminated by removing the assay buffer and
replacing it with ice-cold lysis buffer (100 ml PBS 1 1 M potassium
fluoride 1 1% Triton X-100, pH 7.00) to capture the total cellular
cAMP pool at that moment in time without phosphodiesterase
inhibitor. This step also served to remove putative secreted cAMP
from the measurements. After incubation for .30 minutes at room
temperature with shaking to extract cAMP, a sample of cell lysate
(10 ml) from each well was added to a corresponding well in a HTRF
assay plate.
[3H]ZM-241385 Radioligand Binding Studies. Motulsky-Mahan
kinetic competition binding experiments were performed by measur-
ing the association rate of [3H]ZM-241385 in the presence of test
ligand in membranes prepared from HEK-A2A, as described pre-
viously for this receptor (Guo et al., 2012). To measure occupation of
the binding site in washout experiments, 20 mg of membranes were
incubated with test compound in a volume of 400 ml for 1 hour at 37°C.
Membranes were then pelleted by centrifugation at 16,100 g for
2 minutes and resuspended in 2 ml fresh assay buffer and transferred
to a fresh tube and incubated for 10 minutes on ice. This was repeated
three times to wash the membranes in fresh buffer. Membranes were
then resuspended in 400 ml assay buffer containing 3 nM [3H]ZM-
241385 and incubated for 30 minutes at 37°C to label unoccupied A2A
binding sites.
Immobilized Artificial Membrane Chromatography. Immo-
bilized artificial membrane (IAM) chromatography experiments were
conducted to measure the relative phospholipophilicity (log KIAM) of
each of the compounds since the monolayers of phosphatidlycholine
stationary phase on a silica surface effectively mimic the lipid environ-
ment found in cell membranes (Ong et al., 1995; Pidgeon et al., 1995)
and as such is a parameter used to measure the partitioning of
compounds to fluid membranes. Test compounds (5 ml injections of
10 mM solutions in dimethylsulfoxide) were separated on a Regis IAM
PC DD2 (100  4.6 mm) column preceded by an IAM PC DD2 10/300
guard column, both maintained at 50°C and eluted with 50 mM
ammonium acetate (pH 7.4 adjusted with ammonium hydroxide)
(solvent A) and acetonitrile (solvent B) at a flow rate of 1.0 ml/min,
using a linear gradient (Agilent 1200 series binary pumps, autosam-
pler and temperature control units, Agilent Technologies Ltd., Stock-
port, UK). Initial conditions started at 0% B, which was increased to
100% B over 6 minutes, where it was held for a further 0.5 minute,
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before returning to 0%B over the next 0.5 minute, at which it was held
for a further 2 minutes before the subsequent injection. Detection was
by means of ultraviolet absorption between wavelengths of 254 and
360 nm (0.1minute peakwidth, 2 second response time) via anAgilent
1200 series diode array detector (Agilent Technologies Ltd.). The
retention factor log KIAM was obtained by calculating log[(tR-t0)/t0],
where tR was the retention time of the ultraviolet peak on the gradient
and t0 the corresponding column void volume time for each acquisition
(n5 3, average %CV5 0.17). The equilibrium partition coefficient log
KIAM was subsequently determined by multiplying by a chromato-
graphic hydrophobicity index for immobilized artificial membrane
chromatography at pH 7.4 (CHI IAM7.4), the latter measured for a
diverse set of b-adrenergic compounds and normalized to the values
obtained previously (Sykes et al., 2014).
LogD7.4 Measurements. Lipophilicity measurements were un-
dertaken by calculating the distribution coefficients between 1-octanol
and aqueous buffer at pH 7.4, with the system being validated using
three quality control compounds (high, moderate, and low logD7.4) and
an internal standard (verapamil) all with established logD7.4 values.
Liquid transfers were performed using a Beckman robot (Beckman
Biomek FX, Beckman Coulter UK, High Wycombe, UK). Four
separate dilutions of all phosphate buffer and 1-octanol samples were
analyzed and evaluated to arrive at the measured logD7.4 value.
Compounds in 10 mM DMSO solutions were subjected to the shake
flask technique whereby equal parts of a phosphate buffer (10 mM)
and 1-octanol were vigorously mixed in a separation funnel three
times (at least 15 minutes between each mixing) to saturate the
solutions. The mixture was left overnight to separate the upper
octanol phase from the lower buffer phase before liquid chromatogra-
phy (Waters Acquity UPLC, Milford, MA) separation and mass
spectrometry analysis on a triple quadrupole mass spectrometer
(Waters Micromass TQS running MassLynx 4.1) where the compo-
nents were separated using anWaters Acquity UPLCHSS T3 1.8 mm,
2.1  50 mm column. Calculated logD7.4 values were dependent on
1-octanol solubility as well as mass spectrometry responses and
typical values vary between 0 and 4.
Results
Sustained Wash-resistant A2A Agonist Responses.
We examined the potential for ligand-specific effects on the
durability of A2A cAMP signaling in CHO-A2A cells. A panel
of 18 A2A agonists were chosen from previously disclosed
compounds or those from the AstraZeneca compound library,
as summarized in Table 1 (individual compound structures
are shown in Supplemental Fig. 1). Agonist potency was
determined by concentration-response analysis (sample
curves shown in Supplemental Fig. 2) using the GloSensor
cAMP assay, and physicochemical properties of the com-
pounds were also analyzed (logD7.4 and artificial membrane
partitioning co-efficient log KIAM), as compiled in Table 2.
Sustained effects were investigated inwashout experiments
after chronic agonist treatment, as determined by residual
cAMP responses that persist after removal of free agonist by
infinite dilution. Because a propensity for GPCR ligands to
nonspecifically interact with plastic assay plates can prevent
complete washout from the experimental system and thus
confound the interpretation of sustained effects (Palmgren
et al., 2006; Wennerberg et al., 2010), we designed experi-
ments to avoid this phenomenon. This was achieved by
physically isolating agonist pretreated cells from their
original treatment vessel. Suspensions of cells were first
stimulated with test agonist in tubes (equipotent 20 EC90
concentrations, 2 hours, 37°C), then washed three times by
centrifugation and resuspension in fresh buffer, each time
being transferred to a fresh tube. After a subsequent in-
cubation in fresh buffer to allow putative dissociation of ligand
(1 hour, 37°C) residual cAMP accumulation responses with
the inclusion of a phosphodiesterase inhibitor (40 mM roli-
pram)weremeasured using an endpointHTRF assay. Parallel
compound pre-treated cells were also subsequently directly
exposed to a maximal concentration (20 EC90) of the A2A
agonist UK-432,097 (compound 3cd) during the phosphodi-
esterase inclusion period to determine acute receptor
responsiveness.
Cells pretreated with 3cd, 3ce, 3cg, 3dg, 3eg, 3ch, 3dh, and
3eh demonstrated significantly increased cAMP accumulation
compared with cells pretreated with vehicle control (P, 0.05,
0.01, or 0,001; ANOVA Dunnett’s posttest; n 5 3–5; Fig. 1A).
In contrast, the effects of 1aa, 2bb, 2cb, 3ab, 3ac, 3ad, 3cf, 3ag,
3ah, and 4 were readily removed by washing as pre-exposure
with these compounds did not elicit a residual response and
cellular cAMP levels returned to baseline (Fig. 1A). Therefore,
sustained wash-resistant agonism occurred for some, but not
all, of the compounds tested, highlighting the potential for
ligand-specific factors that can regulate duration of action.
The magnitude of residual postwash responses relative to
maximal receptor activation measured by direct exposure to
agonist was varied, with 3cg, 3ch, and 3eh pretreated cells
reaching .70%, whereas 3cd, 3dg, and 3eg pretreated cells
were limited to ,25% (Fig. 1A).
Further experiments investigated the wash-resistant ef-
fects of compounds 3cd and 3ch in more detail. Concentration-
response analysis was performed by measuring postwash
cAMP responses after pretreatment with a concentration
range of each compound (2 hours, 37°C) followed by a 1-hour
recovery period. These analyses (Fig. 1B) yielded an EC50 of
TABLE 2
Summary data for A2A agonist pharmacology, physicochemical
properties, and antagonist reversal rate
pEC50 is derived from concentration-response curves using the GloSensor cAMP
assay (Sample curves in Supplemental Fig. 2) measured at 20°C for 100 minutes.
LogD7.4 and log KIAM are experimentally measured physicochemical properties used
as indicators of, respectively, lipophilicity and membrane partitioning. Antagonist
reversal t1/2 to estimated agonist off-rate was derived from normalized antagonist
reversal curves (one-phase exponential decay) shown in Fig. 3. Curves were
constrained to give a minimal response of “0” as incomplete reversal observed over
the time-course. Accurate reversal t1/2 values were difficult to derive for THESE data,
but we can say with confidence that t1/2 . 100 minutes. pEC50 values and reversal
half-life estimates are an average of 3 or 4 experiments performed in triplicate.
Compound pEC50 logD7.4 log KIAM
Antagonist
Reversal t1/2
(min)
1aa 7.30 6 0.19 0.6 1.13 5.50 6 0.28
2bb 6.16 6 0.13 N.T. N.T. 8.14 6 1.07
2cb 5.97 6 0.19 2.6 2.31 4.48 6 0.50
3ab 7.52 6 0.06 20.3 20.57 5.80 6 0.25
3ac 7.18 6 0.14 , -0.8 20.09 8.99 6 0.19
3ad 5.70 6 0.21 0.3 0.86 5.02 6 0.37
3cd 8.32 6 0.07 3.6 2.38 39.99 6 4.41
3ce 6.74 6 0.17 1.9 3.35 6.50 6 0.85
3cf 5.91 6 0.04 0.1 2.74 9.44 6 3.28
3ag 7.53 6 0.06 , -0.1 0.51 10.56 6 0.91
3cg 9.04 6 0.09 3.5 2.56 *309 6 124
3dg 9.01 6 0.13 1.8 1.86 38.29 6 4.80
3eg 9.84 6 0.05 2.25 2.08 63.34 6 3.12
3ah 7.79 6 0.08 , -1 0.66 11.31 6 1.60
3ch 9.89 6 0.10 0 2.87 *417 6 86
3dh 9.35 6 0.10 , -1.1 2.21 39.15 6 9.84
3eh 9.48 6 0.22 20.7 2.42 *151 6 32
4 7.93 6 0.17 0 2.21 6.25 6 0.72
N.T., not tested.
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3.13 6 3.99 and 0.31 6 0.07 nM for 3cd and 3ch, respectively,
which were well matched to potency values estimated with
direct (no wash) stimulation of the receptor (Fig. 1B; Table 2).
The postwash concentration-response curves also yielded
Emax values for 3cd and 3ch, respectively, of 25.59 6 6.32
and 93.036 8.55% of responses achieved with direct maximal
receptor activation, further confirming the difference between
these ligands in the magnitude of sustained wash-resistant
responses.
Next, the durability of postwash responses after application
of a single concentration (EC90) of each agonist were compared
in time course experiments over a 5-hour recovery period (at
37°C) (Fig. 1, C and D). Parallel agonist pretreated cells were
also exposed to excess A2A antagonist (100 nM ZM-241385)
after washout over this time to investigate ligand rebinding,
because this is a potential mechanism for prolonged receptor
effects (Vauquelin and Charlton, 2010). Washing alone causes
"infinite dilution" of unbound ligand and thus any ligand that
remains is either receptor bound or capable of rebinding (i.e.,
not effectively removed from the vicinity of the receptor). The
same is true for washing plus antagonist, although the effect of
rebinding is removed because free receptor sites are occupied
and only prebound agonist can evoke a response. Responses to
3cd were gradually lost over a number of hours, although
38.016 7.37% of initial responses still remained after 5 hours
(Fig. 1C). Because there was little effect of antagonist,
rebinding does not play a role, suggesting instead that slow
dissociation kinetics are the primary cause for slow loss of
response. This is consistent with the drop in Emax alongside
minimal change in potency in postwash concentration-
response curves because for each applied concentration there
is a time-dependent decrease in response but the relative
difference in effect between the applied concentrations is
preserved because dissociation rate is concentration indepen-
dent. In contrast, responses to 3ch were markedly stable, with
little loss of receptor function observed after 5 hours and no
effect of antagonist (Fig. 1D). This observation, coupled with
the lack of change in potency or maximal effect in postwash
concentration-response curves suggests that the sustained
effect of 3ch is predominantly a consequence of preformed
Fig. 1. Sustained wash-resistant A2A ago-
nist response measured by physically isolat-
ing agonist pre-treated cells from the original
treatment vessel. (A) Cells were pre-treated
with 20 EC90 concentrations of each agonist
for 2 hours before washout and incubation in
drug-free buffer for 1 hour (37°C) and mea-
surement of cAMP capture by subsequent in-
clusion of rolipram. Sustained cAMP responses
are normalized to acute responses (20 EC90 of
3cd) measured in parallel in the same popula-
tion of pre-treated cells. *P , 0.05, **P , 0.01;
***P , 0.001 determined by ANOVA with
Dunett’s post-test comparedwithvehicle control
pretreated cells. (B) Concentration-responses
analysis of postwash residual effects of 3cd
(blue circles) and 3ch (red squares). Cells were
pretreatedwith the indicated concentrations of
agonist before residual cAMP response mea-
sured after washout. Responses are normal-
ized to acute responses by direct application of
3cd. For direct comparison, the acute pharma-
cological responses of 3cd (light blue triangles)
and 3ch (light red triangles) in the GloSensor
cAMP assay are shown alongside. (C and D)
Time course of sustained responses after pre-
treatment with EC90 concentrations of 3cd (C)
or 3ch (D) after washout, with (red circles) or
without (blue triangles) subsequent inclusion
of antagonist (100 nM ZM-241385) for the
indicated time. Responses are normalized to
responses measured at 1 hour postwash. Data
represent an average 6 S.E.M. of 3–5 experi-
ments performed in triplicate.
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binding events that persist over the time course of the experi-
ments because of a very slow off-rate.
GloSensor Reversal Assay to Estimate Agonist
Dissociation Kinetics. Themost straightforward explanation
for sustained wash-resistant agonist responses is slow ligand
dissociation kinetics (Hothersall et al., 2016). We therefore
assessed agonist off-rates using the real-time GloSensor
cAMP assay by monitoring antagonist mediated reversal of
pre-established agonist responses. Based on the notion that
antagonist reversal involves competitive displacement of
agonist molecules and therefore requires agonist dissociation,
reversal rate is a surrogate read-out for agonist dissociation
rate (explained pictorially in Fig. 2A). This offers a novel,
straightforward, and relatively high-throughput methodology
to investigate agonist binding kinetics in whole cells.
Cells were incubated with equipotent concentrations of
agonist (EC90), and real-time responses were measured at
room temperature until a relatively stable plateau response
was reached (100 minutes). Excess antagonist (100 nM
ZM-241385) or vehicle was then directly added and sub-
sequent responses continually measured. Sample traces for
1aa and 3cd are shown in Fig. 2, B and C and illustrate that,
upon antagonist addition, cAMP responses decreased to
baseline levels, consistent with complete displacement of
agonist. Comparing the traces for these two compounds shows
clear differences in reversal rate, consistent with differential
dissociation kinetics.
To quantify reversal rates, responses in antagonist-treated
cells were normalized to vehicle control at each time point
(% VEH) and nonlinear regression (one-phase exponential
decay) was performed. The reversal traces (Fig. 3) and best-fit
reversal t1/2 values (Table 2) for our agonist panel revealed
strong ligand-specific differences. 3cg, 3ch, and 3eh had very
slow apparent kinetics, with incomplete reversal over the
measurement time course. Accurate reversal half-lives were
therefore hard to quantify for these compounds, although
we can state with confidence that they were greater than
200 minutes. 3cd, 3dg, 3eg, and 3dh were completely reversed
by antagonist but still had slow reversal rates with t1/2 .
38 minutes. The remaining compounds showed rapid reversal
with t1/2 values, 11.5 minutes, and the most rapidly reversed
compound was 2cb (t1/2 5 4.48 6 0.50 minutes).
Importantly, ZM-241385 was able to competitively antago-
nize agonist responses in this assay when cells were preincu-
bated with the antagonist before addition of 3cd or 3ch at
relevant concentrations (Supplemental Fig. 3, A and B),
demonstrating that a slow or absent reversal effect is not
due to an inability of ZM-241385 to antagonize the responses.
Moreover, consistent results were obtained when the endpoint
cAMP assay was used to measure reversal rates (Supplemen-
tal Fig. 3, C and D), suggesting that the GloSensor system is
an accurate measure of cellular cAMP fluxes.
In general, agonists that displayed sustained wash-
resistant effects were characterized by slow GloSensor
reversal rates, which further supported our hypothesis that
persistent responses can be driven by slow dissociation
kinetics. There appeared to be a hyperbolic relationship
between GloSensor reversal rates and the magnitude of
wash-resistant responses determined with equipotent agonist
concentrations. We therefore examined the relationship be-
tween the log t1/2 values and postwash responses and observed
a linear relationship with a reasonable correlation (r2 5 0.73;
Fig. 2. Explanation and demonstration of the GloSensor reversal assay used to estimate agonist dissociation rate. (A) Schematic cartoon describing the
system. Cells are first incubatedwith agonist (blue circles) to permit assumed equilibrium binding to receptors (red circles), which generates a relatively stable
cAMP response.Excess antagonist (green circles) is then directly added to the cells. Upondissociation of the agonist from the receptor, antagonist thenoccupies
the binding site and prevents further activation by the agonist. This causes cessation of cAMP responses, at a rate that is dependent upon agonist dissociation
kinetics. (B and C) Sample GloSensor reversal traces for 1aa (B) and 3cd (C) demonstrate that reversal rate is agonist dependent. Upon incubation of agonist
(EC90) and generation of relatively stable cAMP responses for 100minutes, addition of vehicle control (blue triangles) has little effect on responses for a further
200minutes. However, addition of antagonist at 100minutes (red circles; 100 nMZM-241385) causes a complete reversal of cAMP response to basal levels. 1aa
reversal is faster, consistent with a more rapid off-rate compared with 3cd. Data represent an average of three experiments performed in triplicate.
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P, 0.0001; n5 18 ligands; Fig. 4). Compound 3ce was a clear
outlier in this analysis because it has a sustained effect but is
rapidly reversed by the antagonist, and when removed the
correlation improved greatly (r2 5 0.89). Intriguingly, the
rapid reversal of 3ce was unique to experiments that used
ZM-241385, because an alternative reversal agent, LUF5834,
was unable to fully reverse 3ce-mediated responses, which
would thus categorize 3ce as a slowly dissociating compound,
Fig. 3. Normalized GloSensor reversal traces for a sample of eighteen A2A agonists at 20°C. (A–R) Stable responses were generated to each agonist
applied at an EC90 concentration (100 minutes, 20°C) before antagonist (100 nM ZM-241385) or vehicle was applied for 200 minutes (20°C). Data points
represent antagonist-treated responses expressed as a percentage of vehicle control for each time point to display reversal rate traces over the
postantagonist period. Best-fit lines represent nonlinear regression one-phase exponential decay from the average 6 S.E.M. of three experiments
performed in triplicate. For example, plots (C) and (D) represent normalized data from Figs. 2B and 4C, respectively.
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as expected from washout experiments (Supplemental Fig.
4A). This anomaly in our data set may point toward a probe-
dependent allosteric interplay between 3ce and ZM-241385
binding and/or function. Indeed, the remaining ligands in our
panel showed good correlation between reversal rates derived
using the two alternative reversal agents, with 3ce being
unique in its ability to discriminate between antagonists
(Supplemental Fig. 4E).
Radioligand Binding to Investigate the Kinetics of
A2A Agonists in Membranes from HEK-A2A Cells. To
further investigate a role for agonist off-rate in driving
sustained responses, we monitored occupation of the A2A
binding site after washout in radioligand binding experi-
ments with [3H]ZM-241385 using a fresh tubes approach
equivalent to our functional studies (Fig. 5A). Membranes
from HEK-A2A cells pretreated with 3cd, 3eg, or 3ch (1 mM,
1 hour, 37°C) had significantly fewer available binding sites
after washing than control untreated membranes (P , 0.05,
0.01, or 0.001 ANOVA with Dunnett’s posttest; n 5 3),
consistent with an inability to remove these ligands bywashing
and persistent occupation of the binding site over this time
course. In contrast, 1aa, which represents an exemplar ligand
without a sustained response and that is rapidly reversed
by antagonist, was readily removed from the binding site
by washing (P , 0.05 compared with vehicle control;
ANOVA with Dunnett’s posttest; n 5 3). Together these
findings corroborate our cAMP reversal data and identify
persistent ligand binding as an important factor for sus-
tained effects.
We next sought to quantify A2A agonist binding kinetics
using the Motulsky-Mahan competition radioligand binding
with [3H]ZM-241385, as described previously for this receptor
(Guo et al., 2012). Initial experiments performed at 4°C
yielded residence time estimates (Supplemental Fig. 5, A
and B). However, discrepancies between these values and our
functional cAMP data suggested that low temperature may
have caused an underestimation of residence time. Kinetic
experiments were therefore performed at room temperature.
Although accurate estimation of residence time is technically
challenging at increased temperature, we were able to calcu-
late a kinetic rate index (KRI), which offers a qualitative
assessment of binding kinetics (Guo et al., 2013) (Fig. 5B). KRI
analysis showed that 3cd and 3ch have long residence times
with respective KRI values of 6.4 and 2.6, and both causing
characteristic "overshoot" in [3H]ZM-241385 association
curves. In summary, radioligand binding studies confirm that
3cd and 3ch have slow A2A dissociation kinetics, although the
rank order of estimated off-rate is different to the functional
reversal rates and may point to subtleties in the ability of
these two indirect techniques to determine binding kinetics.
Importantly, our data do not support a role for a change in cell
background, the use of isolated membranes or a different
buffer system in influencing these discrepancies (Supplemen-
tal Fig. 5, C–E).
Adenosine Receptor Specificity of Sustained Agonism.
A selection of compounds were profiled at the adenosine
A2B receptor using a stable CHO-A2B cell line of the same
parental background, at which they demonstrated robust
cAMP stimulation responses (Supplemental Fig. 6). cAMP
responses to 3ab, 3cd, 3eg, and 3ch (EC90 for A2B)were rapidly
reversed by antagonist (2 mM ZM-241385) with t1/2 , 3 min-
utes measured in the endpoint cAMP assay (Fig. 6A). Fur-
thermore, sustained wash-resistant agonist responses were
either absent (3ab and 3cd) or very weak (3eg and 3ch) at A2B
(Fig. 6B). Together, these findings indicate that the slow
dissociation kinetics and robust sustained agonism of these
compounds are not evident at A2B, being instead A2A-specific
Fig. 5. [3H]ZM-241385 binding experiments. (A) Washout experiments
to investigate the persistence of binding site occupation by A2A ago-
nists. HEK-A2A membranes were incubated with 1aa, 3cd, 3eg, 3ch, or
4 (1 mM, 1 hour, 37°C) before washing. Membranes were then incubated
with [3H]ZM-241385 (30 minutes, 37°C) before separation of unbound
radioligand by vacuum filtration. *P , 0.05, **P , 0.01; ***P , 0.001
repeated-measure ANOVA with Dunnett’s post-test compared with
untreated binding signal. (B) [3H]ZM-241385 association rate measured
at room temperature under control conditions (green squares) or in the
presence of 350 nM 3cd (blue triangles) or 120 nM 3ch (red circles).
Fig. 4. Correlation of sustained wash-resistant agonist responses and the
reversal rates of agonists in the GloSensor assay. Linear regression plot of
log converted reversal t1/2 values (from Table 2) against sustained
responses (from Fig. 1A above). Compound 3ce is represented as a red
circle, to highlight that is an outlier. Data from Table 2 is plotted on the
x-axis and data from Fig. 1A is plotted on the y- axis.
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phenomena. This suggests a predominant role for the receptor
binding site rather than non-specific effects of the cellular/
experimental system.
A2A Agonist Temporal Response Profiles in an
Endogenous Expression System. To validate the physio-
logic relevance of our findings, we also investigated A2A
agonist responses in an endogenous receptor expression
system. Human neuroblastoma SH-SY5Y cells were used as
these demonstrated robust and predominantly A2A-mediated
cAMP responses, based on the high potency of 1aa, 3cd, and
3ch, and their sensitivity to an A2A-selective antagonist
(Supplemental Fig. 7). In time-course experiments, cells were
stimulated with these agonists (at an EC90 concentration as
determined in SH-SY5Y cells, 100 minutes) before direct
addition of either vehicle control or antagonist (100 nM
ZM-241385) and incubation for a time course over 3 hours
(Fig. 7, A–F). When performed at room temperature (Fig. 7, A,
C, and E), these time courses were consistent with data from
our recombinant expression system; agonist responses were
stable over time in control (no antagonist) treatment. Antag-
onist addition reversed the responses rapidly for 1aa (com-
plete reversal within the earliest time-point), slowly for 3cd
(approximate t1/2 of 1 hour), and had little effect on 3ch,
highlighting differences in their off-rates that agree with
GloSensor reversal data in our recombinant cell line. When
performed at 37°C (Fig. 7, B, D, and F), some interesting
differences with our CHO-A2A system were observed as
agonist responses were less stable over time in control time
courses, with gradual reduction in cAMP levels to baseline
levels. Despite this, enough response window remained to
observe antagonist-mediated reversal after 1 and 2 hours,
where and 1aa and 3cd were significantly reversed, whereas
3ch remained unaffected. Thus, 3ch appears to have a slow off-
rate at physiologic temperature in these cells. However, these
findings suggest that in some cell backgrounds, cellular
mechanisms that dampen receptor responses over time may
limit the long duration of action of sustained compounds at
37°C. Multiple functionally and temporally distinct mecha-
nisms have been shown to cause agonist-driven dampening of
A2A responses (Chern et al., 1993, 1995; Palmer et al., 1994).
We speculate that SH-SY5Y cells are more susceptible to a
gradual loss of A2A responsiveness because they are better
equipped than CHO cells with the cellular machinery involved
in the downregulation of receptors and/or signaling proteins.
Nevertheless, robust responses remain intact for a number of
hours of chronic agonist stimulation in SH-SY5Y cells, and the
rapid desensitization profile typical of GPCRs is not observed,
offering the opportunity for prolonged agonist effects.
The ability of these compounds to display sustained wash-
resistant agonist responses was investigated in SH-SY5Y cells
with a 1 hour postwash recovery time at 37°C (Fig. 7G). Cells
pretreated with 3ch had significantly elevated residual cAMP
response after washout compared with control (P , 0.01;
ANOVA with Dunett’s post-test; n 5 3), confirming that cell/
receptor-mediated sustained agonism could occur at the
endogenously expressed receptor. Cells pre-exposed to 1aa or
3cd did not have increased residual cAMP responses. That
postwash responses are absent in 3cd pretreated cells may
point toward the weak sustained effects of this compound
being compounded by loss of function by downregulation of
overall receptor responsiveness. Indeed, wash-resistant re-
sponses to 3cd (and 3ch) could be observed at room tempera-
ture where downregulation is not pronounced (Fig. 7H). In
summary, cell-specific factors can influence persistent agonist
responses.
Discussion
In this study we investigated the in vitro temporal response
profiles of a panel of A2A agonists. Because there is good
evidence for the clinical relevance of the duration of action of
these drugs, we sought to better understand the mechanisms
behind these properties. Our data show that some agonists
can continue to activate the receptor for at least a number of
hours after removal of free ligand by infinite dilution, whereas
others are readily removed by washing. This suggests that
certain ligand-specific properties can regulate duration of
action after washing and confer sustained agonism. Similar
phenomena have been observed for a growing number of
Fig. 6. Investigating the effect of some A2A agonists at the A2B receptor.
(A) Antagonist reversal of agonists at A2B using the endpoint cAMP assay.
CHO-A2B cells were incubated with EC90 (at A2B) concentrations of 3ab
(red), 3cd (green), 3eg (blue), or 3ch (purple) for 2 hours at room
temperature before addition of antagonist (2 mM ZM-241385) or vehicle
for the indicated times. Data points represent antagonist-treated cAMP
responses normalized to vehicle control at each time point. Best-fit lines
represent nonlinear regression one-phase exponential decay from an
average 6 S.E.M. of three experiments performed in triplicate. (B)
Sustained agonism at in CHO-A2B cells. Sustained cAMP responses were
measured in washout experiments, measuring residual cAMP responses
after pretreatment of CHO-A2B cells with EC90 concentrations of 3ab, 3cd,
3eg, and 3ch. cAMP responses are normalized to acute responses (20
EC90 of NECA) measured in parallel in the same population of pretreated
cells. **P , 0.01; ***P , 0.001 as determined by repeated-measure
ANOVA with Dunnett’s post-test compared with responses in vehicle
control pretreated cells. Data represent an average of three experiments
performed in triplicate.
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GPCR agonists, although it is often challenging to determine
the precisemechanisms throughwhich this occurs (Hothersall
et al., 2016).
We hypothesized that either slow dissociation kinetics
or rebinding of agonist molecules could drive sustained
responses and sought to delineate these mechanisms by
examining the ability of an antagonist to interrupt agonist
responses. Rebinding can allow multiple sequential short-
lived binding events, whereas slow kinetics involve singular
long-lived binding events, meaning that only the former
is susceptible to antagonist reversal effects as the agonist
dissociates to leave free binding sites. Together, our findings
are consistent with A2A agonist duration of action in cellular
experiments that is governed by their dissociation kinetics from
cell surface receptors. In other words, after washing, predomi-
nantly receptor-bound agonist remains, and responses are lost as
a function of the rate at which agonist/receptor complexes
dissociate. This is supported by the following pieces of evidence:
1. Sustained agonists were characterized by slow antag-
onist reversal rates, and there is a correlation between
reversal rate and the magnitude of sustained agonism
(Fig. 4).
Fig. 7. Temporal response profiles of A2A agonists at
endogenously expressed receptors in SH-SY5Y cells using
the endpoint cAMP assay. (A–F) Time course experiments
determining agonist responses stability and the ability of an
antagonist (100 nM ZM-241385) to reverse these. Experi-
ments were performed at either room temperature (A, C, E)
or 37°C (B, D, F). Cells were incubated with EC90 con-
centrations of 3cd (A, B), 3ch (C, D), or 1aa (E, F) for
100 minutes, before direct addition of antagonist (red) or
vehicle (blue) in a 1:10 dilution and further incubation for
the indicated times, followed by direct addition of rolipram
(in a 1:1 dilution) for 45 minutes. *P , 0.05, **P , 0.01;
***P , 0.001 as determined by repeated-measure ANOVA
with Bonferroni’s post-test comparing antagonist versus
vehicle treated responses for the each time point. (G–H)
Sustained agonist responses measured in washout experi-
ments. Suspensions of SH-SY5Y cells were pre-treated with
20 EC90 concentrations of each agonist (2 hours) at 37°C
(G) or room temperature (H) before washout and recovery in
drug-free buffer for 1 hour (37°C) and measurement of
cAMP capture by subsequent inclusion of rolipram at the
relevant temperature. **P, 0.01; ***P, 0.001 determined
by repeated-measure ANOVA with Dunnett’s post-test
compared with vehicle control.
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2. Radioligand binding experiments suggest that sus-
tained A2A agonists persistently occupy the binding
site after washout. Moreover, sustained agonists have
a long residence time, whereas a readily washed ligand
has rapid kinetics.
3. Little/no potency is lost when comparing postwash
agonist concentration responses with their direct acute
receptor stimulation (Fig. 1B). This indicates that we
are measuring the same ligand/receptor interactions
in both cases, instead of a requirement for a pool of
nonreceptor-bound ligand that is resistant to washing
(i.e., rebinding).
4. Sustained agonist responses are largely insensitive
to antagonist reversal (Fig. 1, C and D), suggesting that
a single stable binding event rather than rebinding
mediates postwash responses.
5. Sustained agonist responses are specific for A2A and
are greatly reduced at A2B, whereas the slowly
dissociating profile of such ligands is lost at A2B. This
strongly suggests that it is the A2A binding site rather
than the cellular background that is driving the effect
and is thus specific to the pharmacology of ligand/A2A
interactions (i.e., agonist off-rate). Rebinding-type mech-
anisms would be expected to be target-independent,
being a product of the ligand diffusion limitations in
that system.
There is precedent for slow agonist dissociation kinetics
regulating a long agonist duration of action atmultiple GPCRs
(Haskell-Luevano et al., 1996; Ferrandon et al., 2009;
Andreassen et al., 2014; Hothersall et al., 2015; Nishiyama
and Hirai, 2015). Our findings are also consistent with
previous observations that the irreversibly binding A2A
agonist DITC-APEC can exert sustained activation in intact
tissue that cannot be reversed by antagonist (Niiya et al.,
1993). Clearly, persistent agonist responses will be facilitated
by a low level of receptor regulatory processes that normally
serve to dampen receptor responsiveness (Hothersall et al.,
2016). Indeed, a lack of desensitization and internalization as
was previously demonstrated for A2A (Zezula and Freissmuth,
2008), although other investigators have observed agonist-
driven loss of A2A responsiveness, which points toward an
important role for cellular context (Chern et al., 1993, 1995;
Palmer et al., 1994). In endogenously expressing SH-SH5Y
cells we do observe a slow loss of A2A function that imparts some
limit on agonist effects over a number of hours. Importantly, in
a number of physiologically relevant settings (Abbracchio et al.,
1992; Niiya et al., 1993; Koshiba et al., 1997), including
in vivo (Adami et al., 1995), A2A agonist responses have been
shown to be stable over time. Thus, a good understanding of
receptor regulatory processes in target tissues will be crucial
to fully understand and characterize the clinical profile of
GPCR agonist drugs.
There is a burgeoning understanding of SAR that underpins
the binding kinetics of GPCR ligands, which is anticipated to
benefit greatly drug discovery. The sustained A2A agonists
identified in this study are characterized by lipophilic N6
substitutions as well as bulky C2 substituents, and wash-
resistant responses are lost when these groups are removed or
replaced (structures shown in Table 1 and washout data
summarized in Fig. 1A). When the N6 group is removed from
sustained compounds (as in 3cd to 3ad, 3cg to 3ag, or 3ch to
3ah) wash resistance is lost and reversal rate is greatly
accelerated. Modifying the N6 group also influences these
kinetics parameters (as evidenced by differences between
3ch, 3dh, and 3eh, as well as 3cg, 4dg, and 3eg). Equally,
when the N6 group is maintained but the C2 is removed,
sustained responses are absent (compound 2cb), and modi-
fying the C2 group of N6 substituted compounds greatly
influences kinetic parameters (compare the responses to 3cd,
3ce, 3cf, 3cg, and 3ch). Therefore, both N6 and C2 groups
contribute to binding kinetics, and the appropriate sub-
stitution of both within the same molecule is required for
persistent receptor activation.
With the benefit of a wealth of published structural biology
data for A2A, we were able to predict the manner in which
agonist interactions in the binding pocket might confer slow
off-rate. Comparing the crystal structures of A2A bound to
the substituted agonist 3cd (UK-432,097) (Xu et al., 2011)
and the unsubstituted agonist 3ab (NECA) (Lebon et al.,
2011), it is clear that N6/C2 substituents of the UK-432,097
molecule make unique interactions with the receptor. Ac-
cordingly, modeling studies have identified three main
“subpockets” within the A2A binding site that, respectively,
interact with the adenosine core, the N6, and the C2 parts of
UK-432,097, with the latter two being empty with unsub-
stituted ligands (Deflorian et al., 2012). Furthermore, mo-
lecular dynamics simulations suggest that UK-432,097
influences receptor conformational space quite differently
to adenosine (Lee and Lyman, 2012). We propose a model
whereby concurrent strong interactions within both the
hydrophobic N6 pocket and C2 pocket hold the adenosine
core of the agonist tightly in the A2A binding site to promote
stable slowly dissociating ligand/receptor complexes and
hence persistent activation. It is feasible that the loss of
sustained responses of C2/N6 substituted compounds at the
closely related A2B receptor are due to differences in
accommodation of the A2B binding pocket for these groups.
Indeed, the tyrosine271 residue of A2A is important for C2-
substituent binding interactions (Deflorian et al., 2012), and
this is changed to asparagine in A2B, consistent with a
prominent role of this group in regulating duration of
binding. Modeling studies alongside receptor mutagenesis
will be an exciting avenue to validate this hypothesis and
help fully understand compound SAR.
The N6 substituents of the sustained compounds confer
lipophilicity (high logD7.4) and/or membrane partitioning
properties (high log KIAM) (Table 2). Interestingly, log KIAM
and logD7.4 can change independently of each other across
related compounds. For example, comparing 3ch and 3cg the
quaternization of the pryridine nitrogen in the C2-substituent
of the former to form a methylpyridinium salt causes a large
drop in logD7.4 (from 3.5 to 0), whereas log KIAM is increased
(from 2.56 to 2.87). Although we originally hypothesized that
membrane partitioning (log KIAM) might be a mechanism for
sustained responses, as has been suggested for other GPCR
agonists (Teschemacher and Lemoine, 1999; Austin et al.,
2003; Hothersall et al., 2015), this does not appear to drive the
persistent activity of the compounds tested here because the
evidence listed above for slow dissociation kinetics generally
excludes this phenomenon. Overall compound lipophilicity
(high logD7.4) is not a prerequisite for sustained agonism, but
our data suggest that lipophilic N6 substituents in particular
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are important in conferring stable binding interactions. For
example, 3ch is amphiphilic and charged but contains a highly
lipophilic biphenyl N6 substituent that appears to interact
favorably with the chemistry of the N6 subpocket to help
promote a sustained response. This highlights that high
lipophilicity logD7.4 is not required for slow dissociation and
that specific local interactions have more of an influence.
In summary, we show that slow dissociation kinetics can
control the duration of action of A2A agonists in a cellular
setting. We suggest that key regions within the A2A binding
pocket underlie this effect and that N6 and C2 substituted
compounds similar toUK-432,097 (3cd) achieve stable binding
by interacting with these. Whereas this stable binding effect is
clearly evident in UK-432,097, it is greatly enhanced by
modifying the C2 group for compounds such as 3cg and 3ch.
It is tempting to speculate that this could offer a means to
improve the clinical pharmacology of A2A ligands by extend-
ing duration of action. We anticipate that this SAR will prove
valuable information for drug discovery at this target by
informing the rational design of novel A2A agonists for
optimized effect duration and improved pharmacotherapeutic
profiles.
Acknowledgments
The authors thank Alastair Brown (Heptares Therapeutics and
AstraZeneca) for initiating and inspiring this project andMark Timms
(AstraZeneca) for assistance in obtaining and collating logD7.4 data.
The authors are grateful to the scientists at WuXi PharmaTech and
BioDuro who synthesised the AstraZeneca proprietary compounds
used in this study.
Authorship Contributions
Participated in research design: Hothersall, Guo, Sarda, Chen,
Waring, IJzerman, Hill, Dale, and Rawlins.
Conducted experiments: Hothersall, Guo, Sarda, and Keur.
Contributed to reagents or analytic tools: Hothersall, Guo, Sarda,
Chen, and Waring.
Performed data analysis: Hothersall, Guo, Sarda, and Chen.
Wrote or contributed to the writing of the manuscript: Hothersall,
Guo, Sarda, Sheppard, Chen, Waring, IJzerman, and Rawlins.
References
Abbracchio MP, Fogliatto G, Paoletti AM, Rovati GE, and Cattabeni F (1992)
Prolonged in vitro exposure of rat brain slices to adenosine analogues: selective
desensitization of adenosine A1 but not A2 receptors. Eur J Pharmacol 227:
317–324.
Adami M, Bertorelli R, Ferri N, Foddi MC, and Ongini E (1995) Effects of re-
peated administration of selective adenosine A1 and A2A receptor agonists on
pentylenetetrazole-induced convulsions in the rat. Eur J Pharmacol 294:
383–389.
Andreassen KV, Hjuler ST, Furness SG, Sexton PM, Christopoulos A, Nosjean O,
Karsdal MA, and Henriksen K (2014) Prolonged calcitonin receptor signaling by
salmon, but not human calcitonin, reveals ligand bias. PLoS One 9:e92042.
Åstrand ABM, Lamm Bergström E, Zhang H, Börjesson L, Söderdahl T, Wingren C,
Jansson A-H, Smailagic A, Johansson C, Bladh H, et al. (2015) The discovery of a
selective and potent A2a agonist with extended lung retention. Pharmacol Res
Perspect 3:e00134.
Austin RP, Barton P, Bonnert RV, Brown RC, Cage PA, Cheshire DR, Davis AM,
Dougall IG, Ince F, Pairaudeau G, et al. (2003) QSAR and the rational design of
long-acting dual D2-receptor/beta 2-adrenoceptor agonists. J Med Chem 46:
3210–3220.
Baines AE, Corrêa SA, Irving AJ, and Frenguelli BG (2011) Differential trafficking of
adenosine receptors in hippocampal neurons monitored using GFP- and super-
ecliptic pHluorin-tagged receptors. Neuropharmacology 61:1–11.
Bridges AJ, Moos WH, Szotek DL, Trivedi BK, Bristol JA, Heffner TG, Bruns RF,
and Downs DA (1987) N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor
agonist with antipsychotic-like activity. J Med Chem 30:1709–1711.
Cerqueira MD (2004) The future of pharmacologic stress: selective A2A adenosine
receptor agonists. Am J Cardiol 94: 33D–42D.
Charalambous C, Gsandtner I, Keuerleber S, Milan-Lobo L, Kudlacek O, Freissmuth
M, and Zezula J (2008) Restricted collision coupling of the A2A receptor revisited:
evidence for physical separation of two signaling cascades. J Biol Chem 283:
9276–9288.
Chen JF, Eltzschig HK, and Fredholm BB (2013) Adenosine receptors as drug targets–
what are the challenges? Nat Rev Drug Discov 12:265–286.
Chern Y, Chiou JY, Lai HL, and Tsai MH (1995) Regulation of adenylyl cyclase type
VI activity during desensitization of the A2a adenosine receptor-mediated cyclic
AMP response: role for protein phosphatase 2A. Mol Pharmacol 48:1–8.
Chern Y, Lai HL, Fong JC, and Liang Y (1993) Multiple mechanisms for de-
sensitization of A2a adenosine receptor-mediated cAMP elevation in rat
pheochromocytoma PC12 cells. Mol Pharmacol 44:950–958.
Copeland RA, Pompliano DL, and Meek TD (2006) Drug-target residence time
and its implications for lead optimization. Nat Rev Drug Discov 5:730–739.
de Lera Ruiz M, Lim YH, and Zheng J (2014) Adenosine A2A receptor as a drug
discovery target. J Med Chem 57:3623–3650.
Deflorian F, Kumar TS, Phan K, Gao ZG, Xu F, Wu H, Katritch V, Stevens RC,
and Jacobson KA (2012) Evaluation of molecular modeling of agonist binding in
light of the crystallographic structure of an agonist-bound A₂A adenosine receptor.
J Med Chem 55:538–552.
Ferrandon S, Feinstein TN, Castro M, Wang B, Bouley R, Potts JT, Gardella TJ,
and Vilardaga JP (2009) Sustained cyclic AMP production by parathyroid hormone
receptor endocytosis. Nat Chem Biol 5:734–742.
Field JJ, Lin G, Okam MM, Majerus E, Keefer J, Onyekwere O, Ross A, Campigotto
F, Neuberg D, Linden J, et al. (2013) Sickle cell vaso-occlusion causes activation of
iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson.
Blood 121:3329–3334.
Gao ZG and Jacobson KA (2011) Emerging adenosine receptor agonists: an update.
Expert Opin Emerg Drugs 16:597–602.
Gnad T, Scheibler S, von Kügelgen I, Scheele C, Kilic A, Glöde A, Hoffmann LS,
Reverte-Salisa L, Horn P, Mutlu S, et al. (2014) Adenosine activates brown
adipose tissue and recruits beige adipocytes via A2A receptors. Nature 516:
395–399.
Guo D, Hillger JM, IJzerman AP, and Heitman LH (2014) Drug-target residence
time–a case for G protein-coupled receptors. Med Res Rev 34:856–892.
Guo D, Mulder-Krieger T, IJzerman AP, and Heitman LH (2012) Functional efficacy
of adenosine A₂A receptor agonists is positively correlated to their receptor resi-
dence time. Br J Pharmacol 166:1846–1859.
Guo D, van Dorp EJ, Mulder-Krieger T, van Veldhoven JP, Brussee J, Ijzerman AP,
and Heitman LH (2013) Dual-point competition association assay: a fast and high-
throughput kinetic screening method for assessing ligand-receptor binding kinet-
ics. J Biomol Screen 18:309–320.
Haskell-Luevano C, Miwa H, Dickinson C, Hadley ME, Hruby VJ, Yamada T,
and Gantz I (1996) Characterizations of the unusual dissociation properties of
melanotropin peptides from the melanocortin receptor, hMC1R. J Med Chem 39:
432–435.
Hothersall JD, Bussey CE, Brown AJ, Scott JS, Dale I, and Rawlins P (2015) Sus-
tained wash-resistant receptor activation responses of GPR119 agonists. Eur J
Pharmacol 762:430–442.
Hothersall JD, Brown AJ, Dale I, and Rawlins P (2016) Can residence time offer a
useful strategy to target agonist drugs for sustained GPCR responses? Drug Discov
Today 21:90–96.
Koshiba M, Kojima H, Huang S, Apasov S, and Sitkovsky MV (1997) Memory of
extracellular adenosine A2A purinergic receptor-mediated signaling in murine
T cells. J Biol Chem 272:25881–25889.
Lebon G, Edwards PC, Leslie AG, and Tate CG (2015) Molecular Determinants of
CGS21680 Binding to the Human Adenosine A2A Receptor. Mol Pharmacol 87:
907–915.
Lebon G, Warne T, Edwards PC, Bennett K, Langmead CJ, Leslie AG, and Tate CG
(2011) Agonist-bound adenosine A2A receptor structures reveal common features
of GPCR activation. Nature 474:521–525.
Lee JY and Lyman E (2012) Agonist dynamics and conformational selection during
microsecond simulations of the A(2A) adenosine receptor. Biophys J 102:
2114–2120.
Mantell S, Jones R, and Trevethick M (2010) Design and application of locally de-
livered agonists of the adenosine A(2A) receptor. Expert Rev Clin Pharmacol 3:
55–72.
Marumoto R, Yoshioka Y, Honjo M, and Kawazoe K (1974), inventors, Takeda
Chemical Industries Limited, assignee. 2,6-diaminonebularinderivate 2,6-
diaminonebularinderivate. Patent DE2359536 A1. 1973 Nov 29.
Niiya K, Jacobson KA, Silvia SK, and Olsson RA (1993) Covalent binding of a se-
lective agonist irreversibly activates guinea pig coronary artery A2 adenosine re-
ceptors. Naunyn Schmiedebergs Arch Pharmacol 347:521–526.
Nishiyama K and Hirai K (2015) In vitro comparison of duration of action of mela-
tonin agonists on melatonin MT receptor: possible link between duration of action
and dissociation rate from receptor. Eur J Pharmacol 757:42–52.
Ong S, Liu H, Qiu X, Bhat G, and Pidgeon C (1995) Membrane partition coefficients
chromatographically measured using immobilized artificial membrane surfaces.
Anal Chem 67:755–762.
Palmer TM, Gettys TW, Jacobson KA, and Stiles GL (1994) Desensitization of the
canine A2a adenosine receptor: delineation of multiple processes. Mol Pharmacol
45:1082–1094.
Palmgren JJ, Monkkonen J, Korjamo T, Hassinen A, and Auriola S (2006) Drug
adsorption to plastic containers and retention of drugs in cultured cells under
in vitro conditions. Eur J Pharm Biopharm 64: 369–378.
Pidgeon C, Ong S, Liu H, Qiu X, Pidgeon M, Dantzig AH, Munroe J, Hornback WJ,
Kasher JS, Glunz L, et al. (1995) IAM chromatography: an in vitro screen for
predicting drug membrane permeability. J Med Chem 38:590–594.
Sato N, Yuki Y, Shinohara H, Takeji Y, Ito K, Michikami D, Hino K, and Yamazaki H
(2010) inventors, Otsuka Pharmaceutical Co Ltd, assignee. A novel cyanopyr-
imidine derivative. Patent WO/2010/090299. 2010 Dec 8.
Sykes DA, Parry C, Reilly J, Wright P, Fairhurst RA, and Charlton SJ (2014) Ob-
served drug-receptor association rates are governed by membrane affinity: the
Slow Agonist Dissociation Kinetics Drive Sustained A2A Responses 37
 at A
SPET Journals on February 10, 2017
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
importance of establishing “micro-pharmacokinetic/pharmacodynamic relation-
ships” at the b2-adrenoceptor. Mol Pharmacol 85:608–617.
Teschemacher A and Lemoine H (1999) Kinetic analysis of drug-receptor interactions
of long-acting beta2 sympathomimetics in isolated receptor membranes: evidence
against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl
cyclase. J Pharmacol Exp Ther 288:1084–1092.
Vauquelin G and Charlton SJ (2010) Long-lasting target binding and rebinding as
mechanisms to prolong in vivo drug action. Br J Pharmacol 161:488–508.
Wennerberg M, Balendran A, Clapham JC, and Vauquelin G (2010) Unravelling the
complex dissociation of [(3)H]-rimonabant from plated CB(1) cannabinoid receptor-
expressing cells. Fundam Clin Pharmacol 24:181–187.
Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao ZG, Cherezov V, and Stevens
RC (2011) Structure of an agonist-bound human A2A adenosine receptor. Science
332:322–327.
Zezula J and Freissmuth M (2008) The A(2A)-adenosine receptor: a GPCR with
unique features? Br J Pharmacol 153 (Suppl 1):S184–S190.
Address correspondence to: Philip Rawlins, AstraZeneca, Discovery
Sciences, Unit 310 – Darwin Building, Cambridge Science Park, Milton Road,
Cambridge, CB4 0WG. E-mail: philip.rawlins@astrazeneca.com
38 Hothersall et al.
 at A
SPET Journals on February 10, 2017
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
